Back to home
DEALS & FUNDINGApril 15, 2026·4 min read
Eli Lilly Acquires CrossBridge Bio for Dual-Payload ADC Technology
Lilly bets on next-generation dual-payload ADCs with the acquisition of CrossBridge Bio, whose CBB-120 platform delivers two cytotoxic agents per antibody for potentially superior tumor killing.
The full analysis is published in the weekly biotech.today newsletter — subscribe for free to get the next issue in your inbox.